PCMA takes on biotechs looking to protect profits | PCMA: Biotech manufacturers lobby states to restrict access to biosimilar medications | Agency releases final Sunshine Act rule
Web Version
 
February 4, 2013
FOLLOW PCMA ON TWITTER  Twitter
PCMA SmartBrief
News for the PBM Industry
SIGN UP|FORWARD|ARCHIVE

Featured Story
PCMA takes on biotechs looking to protect profits
PCMA has launched a campaign to counter manufacturers' attempts to impede access to biosimilar drugs. The drugmakers are trying to preempt the FDA by creating a patchwork of state laws that will make it difficult for pharmacists to substitute less-expensive biosimilar drugs when appropriate, raising costs for patients and employers. Sarasota Herald-Tribune (Fla.) (1/31), InsideHealthPolicy.com (subscription required) (2/1), PharmaTimes (U.K.) (2/4)
Share: LinkedInTwitterFacebookGoogle+Email
Legislative & Regulatory News
Agency releases final Sunshine Act rule
CMS on Friday released the final rule for the Physician Payments Sunshine Act, requiring drug and device companies to gather information on gifts, payments and other value transfers provided to doctors and teaching hospitals starting Aug. 1. The rule also requires manufacturers and group purchasing organizations to report ownership and investment interests by physicians. Modern Healthcare (subscription required) (2/1)
Share: LinkedInTwitterFacebookGoogle+Email
Study finds large premium increases for some under ACA
Premiums for individual health insurance plans for young, healthy men are likely to rise as a result of the Affordable Care Act, though some will receive federal subsidies to offset some of the cost. A survey by the American Action Forum, a group that opposes the ACA, found premiums for an individual policy offering minimal coverage could rise 190% for a 27-year-old nonsmoking male. Politico (Washington, D.C.) (2/4)
Share: LinkedInTwitterFacebookGoogle+Email
Study finds disparity in how doctors prescribe heart drugs
Americans without health coverage are 6% to 12% less likely than those who have insurance to be prescribed drugs for heart disease, according to a study published in the Journal of the American College of Cardiology. Patients treated at clinics where many uninsured patients receive care were the least likely to be prescribed heart drugs. Reuters (2/1)
Share: LinkedInTwitterFacebookGoogle+Email
Drug Industry Spotlight
Report maps psychiatric drug use in the U.S.
Use of antipsychotics, antidepressants and stimulants is 40% greater in parts of the southern U.S. than in other regions, researchers wrote in the journal Health & Place, while patients living in the western U.S. are least likely to take psychiatric medications. "Our work suggests that access to clinical care and pharmaceutical marketing may be critical for understanding who gets treated and how they get treated," said Marissa King of Yale University. HealthDay News (2/1)
Share: LinkedInTwitterFacebookGoogle+Email
SmartQuote
To attain knowledge, add things every day. To attain wisdom, subtract things every day."
-- Laozi,
Chinese philosopher
Share: LinkedInTwitterFacebookGoogle+Email
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 216 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

Contact PCMA
Charles Cote
Vice President, Strategic Communications
(202) 207-3610
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
 
Editor:  Melissa Turner
 
 

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information